BR112019009172A2 - formulações para radioterapia e diagnóstico por imagem. - Google Patents

formulações para radioterapia e diagnóstico por imagem.

Info

Publication number
BR112019009172A2
BR112019009172A2 BR112019009172A BR112019009172A BR112019009172A2 BR 112019009172 A2 BR112019009172 A2 BR 112019009172A2 BR 112019009172 A BR112019009172 A BR 112019009172A BR 112019009172 A BR112019009172 A BR 112019009172A BR 112019009172 A2 BR112019009172 A2 BR 112019009172A2
Authority
BR
Brazil
Prior art keywords
radiotherapy
formulations
diagnostic imaging
diagnostic
imaging
Prior art date
Application number
BR112019009172A
Other languages
English (en)
Inventor
Marie Jeffery Charmaine
Marianne Van Dam Ellen
John Harris Matthew
Original Assignee
Clarity Pharmaceuticals Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016904515A external-priority patent/AU2016904515A0/en
Application filed by Clarity Pharmaceuticals Pty Ltd filed Critical Clarity Pharmaceuticals Pty Ltd
Publication of BR112019009172A2 publication Critical patent/BR112019009172A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0485—Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/025—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus inorganic Tc complexes or compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

formulações para radioterapia e diagnóstico por imagem. a presente invenção relaciona-se a formulações de compostos radiomarcados para o uso em radioterapia e diagnóstico por imagem.
BR112019009172A 2016-11-04 2017-11-02 formulações para radioterapia e diagnóstico por imagem. BR112019009172A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2016904515A AU2016904515A0 (en) 2016-11-04 Formulations for Radiotherapy and Diagnostic Imaging
PCT/AU2017/051205 WO2018081860A1 (en) 2016-11-04 2017-11-02 Formulations for radiotherapy and diagnostic imaging

Publications (1)

Publication Number Publication Date
BR112019009172A2 true BR112019009172A2 (pt) 2019-07-16

Family

ID=62075372

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019009172A BR112019009172A2 (pt) 2016-11-04 2017-11-02 formulações para radioterapia e diagnóstico por imagem.

Country Status (9)

Country Link
US (2) US20190282715A1 (pt)
EP (1) EP3534969A4 (pt)
JP (1) JP7242538B2 (pt)
KR (2) KR102445956B1 (pt)
CN (1) CN110139677A (pt)
AU (1) AU2017354941B2 (pt)
BR (1) BR112019009172A2 (pt)
CA (1) CA3042737A1 (pt)
WO (1) WO2018081860A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195890A1 (en) * 2018-04-11 2019-10-17 Clarity Pharmaceuticals Pty Ltd Formulations and kits for radiotherapy and diagnostic imaging
WO2020021310A1 (en) * 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) Srl Stable, concentrated radionuclide complex solutions
US10596278B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
US10596276B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
KR102643582B1 (ko) * 2018-07-25 2024-03-05 어드밴스드 엑셀러레이터 어플리케이션즈 안정한 농축 방사성 핵종 복합체 용액
EP3976025A4 (en) * 2019-05-24 2023-05-17 Clarity Pharmaceuticals Limited PSMA IMAGING AGENT FORMULATIONS
CN115175910A (zh) * 2019-11-08 2022-10-11 昆士兰大学 放射性标记的靶向配体
MX2022013783A (es) * 2020-05-06 2023-04-19 Univ Cornell Compuestos tratanosticos que contienen cobre y metodos de uso.
US11541134B1 (en) 2021-08-02 2023-01-03 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985240A (en) * 1989-08-09 1999-11-16 Rhomed Incorporated Peptide radiopharmaceutical applications
DK0600992T3 (da) * 1991-08-29 2000-10-09 Mallinckrodt Medical Inc Anvendelse af gentissyre eller gentisylalkohol til stabilisering af radiomærkede peptider og proteiner
WO2008009444A1 (en) * 2006-07-19 2008-01-24 Van Dulmen, Adrianus, A. Use of ethanol for stabilizing a single-vial liquid formulation of a radiolabeled peptide
EP2370447B1 (en) * 2008-12-02 2016-07-27 The University of Melbourne Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals

Also Published As

Publication number Publication date
AU2017354941B2 (en) 2021-02-11
US20210402013A1 (en) 2021-12-30
CN110139677A (zh) 2019-08-16
RU2019116385A (ru) 2020-12-04
CA3042737A1 (en) 2018-05-11
EP3534969A1 (en) 2019-09-11
US20190282715A1 (en) 2019-09-19
KR102445956B1 (ko) 2022-09-22
WO2018081860A1 (en) 2018-05-11
AU2017354941A1 (en) 2019-05-16
KR102484725B1 (ko) 2023-01-06
KR20190094160A (ko) 2019-08-12
JP7242538B2 (ja) 2023-03-20
JP2019533728A (ja) 2019-11-21
EP3534969A4 (en) 2020-07-01
KR20220132033A (ko) 2022-09-29
RU2019116385A3 (pt) 2021-02-12

Similar Documents

Publication Publication Date Title
BR112019009172A2 (pt) formulações para radioterapia e diagnóstico por imagem.
CL2017000554A1 (es) Compuestos terapéuticamente activos y sus métodos de uso
DOP2016000315A (es) Anticuerpos monoclonales contra el epítope de her2 y sus métodos de uso
BR112016018891A2 (pt) anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma
ECSP15026557A (es) Compuestos y sus métodos de empleo
ECSP14014544A (es) Compuestos terapéuticamente activos y sus métodos de uso
BR112016026993A2 (pt) combinação de um anticorpo anti-ccr4 e um agonista 4-1bb para tratar câncer
NI201500140A (es) Compuestos y composiciones terapéuticos
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
BR112017020178A2 (pt) vacina estreptocócica
BR112016029860A2 (pt) conjugados de anticorpo antirreceptor alfa de folato (fra)-fármaco e métodos de uso dos mesmos
BR112016018062A8 (pt) compostos terapêuticos, composição farmacêutica e usos
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
BR112019001233A2 (pt) formulação farmacêutica e uso da mesma
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
CR20160047A (es) Inhibidores de rorc2 y sus métodos de uso
PH12018500701A1 (en) 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer
BR112018012313A2 (pt) composições que compreendem 15-hepe e métodos para uso das mesmas
BR112015031710A2 (pt) anticorpos para o receptor de ldl oxidada similar à lectina 1 e métodos de uso
CL2015002180A1 (es) Terapia de combinación para el tratamiento de neumonía nosocomial
CO2017011295A2 (es) Piroglutamato de vortioxetina
CL2019002733A1 (es) Formulaciones de clorhidrato del ácido 1-amino-1-ciclopropanocarboxílico.
BR112016017620A2 (pt) Composto esteroidal para uso no tratamento da encefalopatia hepática
BR112017009000A2 (pt) apilimod para uso no tratamento de melanoma

Legal Events

Date Code Title Description
B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: CLARITY PHARMACEUTICALS PTY LTD (AU)

Free format text: A FIM DE ATENDER A ALTERACAO DE NOME REQUERIDA ATRAVES DA PETICAO NO 870200142395, DE 11/11/2020, E NECESSARIO APRESENTAR O DOCUMENTO NOTARIZADO E COM APOSTILAMENTO OU LEGALIZACAO CONSULAR, TRADUCAO JURAMENTADA, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA.

B25E Requested change of name of applicant rejected

Owner name: CLARITY PHARMACEUTICALS PTY LTD (AU)

Free format text: INDEFERIDO O PEDIDO DE ALTERACAO DE NOME CONTIDO NA PETICAO 870200142395 DE 11/11/2020, POR AUSENCIA DE CUMPRIMENTO DA EXIGENCIA PUBLICADA NA RPI NO 2623, DE 13/04/2021.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: CLARITY PHARMACEUTICALS PTY LTD (AU)

Free format text: A FIM DE ATENDER A ALTERACAO DE NOME REQUERIDA ATRAVES DA PETICAO NO 870220115401, DE 09/12/2022, E NECESSARIO APRESENTAR O DOCUMENTO NOTARIZADO E COM APOSTILAMENTO OU LEGALIZACAO CONSULAR, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA.

B25E Requested change of name of applicant rejected

Owner name: CLARITY PHARMACEUTICALS PTY LTD (AU)

Free format text: INDEFERIDO O PEDIDO DE ALTERACAO DE NOME CONTIDO NA PETICAO 870220115401 DE09/12/2022, POR AUSENCIA DE CUMPRIMENTO DA EXIGENCIA PUBLICADA NA RPI NO 2735, DE 06/06/2023.

B15Z Prolongation of time limit refused

Free format text: NEGADA A SOLICITACAO DE DEVOLUCAO DE PRAZO REQUERIDA ATRAVES DA PETICAO NO 870240020718 DE 11.03.2024, POR FALTA DE FUNDAMENTACAO LEGAL. A COPIA DO PARECER PODERA SER OBTIDA ATRAVES DO ENDERECO ELETRONICO: WWW.INPI.GOV.BR NO ACESSO RAPIDO = BUSCA DE PROCESSOS = FACA LOGIN COM SENHA OU TECLE CONTINUAR = PATENTE = DIGITE O NUMERO DO PROCESSO = PESQUISAR. PARA ACESSAR, CADASTRE-SE NO PORTAL DO INPI. DESTA DATA CORRE O PRAZO DE 60 (SESSENTA) DIAS PARA EVENTUAL RECURSO DO INTERESSADO.